3-Methoxy-N-methylenebenzeneethanamine | 110339-52-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-Methoxy-N-methylenebenzeneethanamine
• 英文别名: N-[2-(3-methoxyphenyl)ethyl]methanimine
• CAS: 110339-52-1
• 化学式: C₁₀H₁₃NO
• 分子量: 163.219
• InChiKey: PUJUIJJGBPGDAL-UHFFFAOYSA-N

物化性质

• 沸点：
  267.8±42.0 °C(Predicted)
• 密度：
  0.93±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  21.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-Methoxy-N-methylenebenzeneethanamine 在 盐酸 、 氢氧化钾 作用下， 以 水 为溶剂， 反应 1.0h， 生成 6-甲氧基-1,2,3,4-四氢异喹啉
  参考文献：
  名称：

  5-HT7 receptor antagonists

  摘要：

  这项发明涉及对5-HT7受体具有药理活性的化合物，更具体地涉及一些式I的四氢异喹啉取代磺胺基化合物的制备过程，包括含有它们的药物组合物，以及它们用于治疗和/或预防涉及5-HT的疾病，如中枢神经系统紊乱的用途。

  公开号：

  EP1676844A1
• 作为产物：
  描述：

  聚合甲醛 、 3-甲氧基苯乙胺 以 水 为溶剂， 反应 1.0h， 生成 3-Methoxy-N-methylenebenzeneethanamine
  参考文献：
  名称：

  5-HT7 receptor antagonists

  摘要：

  这项发明涉及对5-HT7受体具有药理活性的化合物，更具体地涉及一些式I的四氢异喹啉取代磺胺基化合物的制备过程，包括含有它们的药物组合物，以及它们用于治疗和/或预防涉及5-HT的疾病，如中枢神经系统紊乱的用途。

  公开号：

  EP1676844A1

文献信息

• [EN] NOVEL E,E-DIENE COMPOUNDS AND THEIR USE AS MEDICAMENTS AND COSMETICS<br/>[FR] NOUVEAUX COMPOSÉS E,E-DIÉNIQUES ET LEUR UTILISATION COMME MÉDICAMENTS ET PRODUITS COSMÉTIQUES
  申请人：WOLFF AUGUST GMBH & CO KG ARZNEIMITTEL DR

  公开号：WO2012069605A1

  公开（公告）日：2012-05-31

  The present invention relates to a novel class of E,E-diene compounds and their use as a medicament, preferably as a dermatologic agent, and as a cosmetic. These novel compounds are particularly useful in treating and/or preventing inflammation, irritation, itching, pruritus, pain, oedema and/or pro-allergic or allergic conditions in a patient. Usually they are topically applied to the skin or mucosa in the form of a pharmaceutical or cosmetic composition comprising the compound and a pharmaceutically and/or cosmetically acceptable carrier.

  本发明涉及一种新型的E,E-二烯化合物及其作为药物的用途，优选作为皮肤科药剂和化妆品。这些新型化合物在治疗和/或预防病人的炎症、刺激、瘙痒、瘙痒、疼痛、水肿和/或过敏或过敏性疾病方面特别有用。通常它们以药用或化妆品组合物的形式局部应用于皮肤或粘膜，该组合物包括该化合物和药学和/或化妆学上可接受的载体。
• Inhibitors of Ion Channels
  申请人：Marron Brian Edward

  公开号：US20130072471A1

  公开（公告）日：2013-03-21

  Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides substituted aryl sulfonamides, compositions comprising these compounds, as well as methods of using these compounds or compositions in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrence of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a voltage-gated sodium channel.

  本发明提供了在通过抑制电压门控钠通道中的钠离子流来治疗疾病方面有用的化合物、组合物和方法。更具体地，本发明提供了取代芳基磺酰胺、包含这些化合物的组合物，以及使用这些化合物或组合物治疗中枢或外周神经系统疾病，特别是疼痛和慢性疼痛的方法，通过阻断与所示条件的发生或复发相关的钠通道来实现。本发明的化合物、组合物和方法特别适用于通过抑制电压门控钠通道中的离子流来治疗神经病性或炎症性疼痛。
• INHIBITORS OF ION CHANNELS
  申请人：Marron Brian Edward

  公开号：US20090143358A1

  公开（公告）日：2009-06-04

  Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides substituted aryl sulfonamides, compositions comprising these compounds, as well as methods of using these compounds or compositions in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrence of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a voltage-gated sodium channel.

  本发明提供了化合物、组合物和方法，通过抑制电压门控钠通道中的钠离子流来治疗疾病。更具体地，本发明提供了取代芳基磺酰胺、包含这些化合物的组合物，以及使用这些化合物或组合物治疗中枢或外周神经系统疾病，特别是疼痛和慢性疼痛的方法，通过阻止与所示疾病的发生或复发有关的钠通道。本发明的化合物、组合物和方法特别适用于通过抑制电压门控钠通道中的离子流来治疗神经病理性或炎症性疼痛。
• SAR studies of capsazepinoid bronchodilators. Part 1: The importance of the catechol moiety and aspects of the B-ring structure
  作者：Marı´a F. Dalence-Guzmán、Magnus Berglund、Staffan Skogvall、Olov Sterner

  DOI：10.1016/j.bmc.2007.11.055

  日期：2008.3

  Capsazepine as well as its derivatives and analogues are general inhibitors of constriction of human small airways. From a systematic variation of the capsazepine structure, divided into four regions, SARs were established. This part concerns the catechol moiety of the A-ring as well as the 2,3,4,5-tetrahydro-1H-2-azepine moiety (the B-ring) of capsazepine. It is revealed that a conformational constrain (as a fused ring) is important and that compounds with a six-membered B-ring (as a 1,2,3,4-tetrahydroisoquinoline) in general are more potent than the corresponding isoindoline, 2,3,4,5 -tetrahydro-1H-2-benzazepi ne and 2,3,4,5-tetrahydro-1H-3-benzazepine derivatives. (C) 2007 Elsevier Ltd. All rights reserved.
• EUERBY M. R.; WAIGH R. D., J. CHEM. RES. SYNOP.,(1987) N 2, 36-37
  作者：EUERBY M. R.、 WAIGH R. D.

  DOI：——

  日期：——